<DOC>
	<DOCNO>NCT02307682</DOCNO>
	<brief_summary>The purpose study compare RTH258 ophthalmic solution intravitreal ( IVT ) injection two dosage level aflibercept solution IVT injection ( 2 mg ) subject untreated active choroidal neovascularization ( CNV ) secondary age-related macular degeneration ( AMD ) study eye.This study conduct Argentina , Australia , Brazil , Canada , Chile , Colombia , Costa Rica , Guatemala , Israel , Japan , Mexico , Panama , Peru , New Zealand , US ( include Puerto Rico ) .</brief_summary>
	<brief_title>Efficacy Safety RTH258 Versus Aflibercept</brief_title>
	<detailed_description>This study 3 arm 1:1:1 randomization . Subjects arm visit every 4 week Week 96 . The primary analysis perform Week 48 .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Provide write informed consent Active CNV lesion secondary AMD study eye Intra and/or subretinal fluid affect central subfield study eye BCVA 78 23 letter , inclusive , study eye use Early Treatment Diabetic Retinopathy Study ( ETDRS ) test Other protocoldefined inclusion criterion may apply Any active intraocular periocular infection active intraocular inflammation either eye Fibrosis geographic atrophy Any approve investigational treatment neovascular AMD ( vitamin supplement ) study eye time Any history evidence concurrent intraocular condition study eye , judgment Investigator , could require either medical surgical intervention course study prevent treat visual loss Current vitreous hemorrhage history vitreous hemorrhage study eye within 4 week History evidence surgery study eye , specify protocol Uncontrolled glaucoma study eye Aphakia and/or absence posterior capsule study eye Use corticosteroid , ocular systemic , specify protocol Treatment aflibercept ( EYLEA® ) , bevacizumab ( AVASTIN® ) , ranibizumab ( LUCENTIS® ) , pegaptanib ( MACUGEN® ) nonstudy eye , specify protocol History medical condition , judgment Investigator , would preclude schedule study visit , completion study , safe administration investigational product History hypersensitivity component test article , control article , ophthalmic dye , assess Investigator Pregnant , lactating , woman childbearing potential , unless use effective method contraception dose study treatment Stroke myocardial infarction 90 day period prior enrollment Uncontrolled blood pressure define systolic value ≥ 160 mmHg diastolic value ≥ 100 mmHg Participation investigational drug , biologic , device study , specify protocol Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AMD</keyword>
	<keyword>CNV</keyword>
	<keyword>IVT</keyword>
</DOC>